Pyrin and HIN Domain-Containing Protein 1 (PYHIN1): A Promising Drug Target and Biomarker

Target Name: PYHIN1

NCBI ID: G149628

PYHIN1

Pyrin and HIN Domain-Containing Protein 1 (PYHIN1): A Promising Drug Target and Biomarker

Pyrin and HIN domain-containing protein 1 (PYHIN1) is a protein that has been identified as a potential drug target and biomarker. PYHIN1 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and muscle. It is characterized by the presence of a unique domains: a N-terminal Pyrin domain and a C-terminal HIN domain. The Pyrin domain is known for its ability to form hydrogen bonds, which is involved in various cellular processes, including signaling pathways, DNA replication, and inflammation. The HIN domain is known for its role in protein-protein interactions and is involved in the regulation of cellular processes, such as cell adhesion and migration.

PYHIN1 Functions

PYHIN1 plays a crucial role in various cellular processes in the brain and body. One of its most significant functions is its role in the regulation of neurotransmitter release from neurons. PYHIN1 is involved in the regulation of the release of neurotransmitters, such as dopamine, serotonin, and endocannabinoids. It does this by interacting with the neurotransmitter receptors, which are located in the postsynaptic density of the neuron.

PYHIN1 is also involved in the regulation of pain perception and neuroinflammation. Its role in these processes is mediated by its interaction with various signaling pathways, including the production of reactive oxygen species (ROS) and the production of pro-inflammatory cytokines.

PYHIN1 as a Drug Target

PYHIN1 has been identified as a potential drug target due to its unique functions and its involvement in various cellular processes. One of the primary reasons for its potential as a drug target is its stability and the fact that it is expressed in various tissues, including the brain. This makes it a promising target for small molecules, which can be administered to the brain to modulate its function.

PYHIN1 can be modulated by various small molecules, including inhibitors of its activity, such as small molecule inhibitors, peptides, and antibodies. One of the most promising small molecules is a drug called PF-1012, which is a small molecule inhibitor of PYHIN1. PF-1012 has been shown to block the activity of PYHIN1 and to decrease the production of ROS and pro-inflammatory cytokines.

Another small molecule that has been shown to be effective in modulating PYHIN1 is called PF-256. PF-256 is a peptide that contains two domains: a N-terminal Pyrin domain and a C-terminal HIN domain. PF-256 has been shown to inhibit the activity of PYHIN1 and to decrease the production of ROS and pro-inflammatory cytokines.

PYHIN1 as a Biomarker

PYHIN1 has also been identified as a potential biomarker for various diseases, including neurodegenerative diseases, pain disorders, and autoimmune diseases. This is due to its involvement in the regulation of various cellular processes that are affected in these diseases.

For example, PYHIN1 is involved in the regulation of neurotransmitter release from neurons, which is affected in neurodegenerative diseases. It is also involved in the regulation of pain perception, which is affected in

Protein Name: Pyrin And HIN Domain Family Member 1

Functions: Major mediator of the tumor suppressor activity of IFN in breast cancer cells. Promotes ubiquitination and subsequent degradation of MDM2, which leads to p53/TP53 stabilization. Promotes ubiquitination and subsequent degradation of HDAC1, which in turn enhances maspin expression, and impairs invasive activity of cancer cells

The "PYHIN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PYHIN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets